class="Serp__item__snippet--34vQF">GSK confirmed today that a joint advisory committee to the FDA voted to continue to make Avandia (rosiglitazone) available to appropriate patients with the majority of the members voting to either modify (13) or remove (7) the Risk Evaluation and Mitigation...